CP143754121 | Merck announces Molnupiravir manufacturing in Canada for COVID-19

CP152985172 | Newsroom Ready: Ontario residents react to mask mandates being lifted in most public spaces

CP112898221 | Newsroom Ready: Health Canada approves COVID-19 vaccine

CP18981855 | Newsroom Ready: Health Canada aims to speed COVID-19 vaccine approvals: Tam

CP17178071 | Newsroom Ready: Canada's $850M promise for international COVID-19 fight 'only a beginning'

CP19569821 | Newsroom Ready: Canada buys options for fifth potential COVID-19 vaccine

CP111820471 | Newsroom Ready: National plans for COVID-19 vaccine distribution in the works: Hajdu

CP18576697 | Newsroom Ready: As Russia moves ahead with COVID-19 vaccine, Tam expresses confidence in Health Canada's process

CP142522771 | Newsroom Ready: Child COVID-19 vaccinations ramp up in Ontario

CP168286749 | Newsroom Ready: Health Canada approves updated Moderna vaccine for COVID-19

Placeline/People

City Vaughan

Country Canada

Newsroom Ready: Merck announces Molnupiravir manufacturing in Canada for COVID-19

Merck has announced a partnership with Thermo Fisher Scientific to manufacture Molnupiravir, an oral antiviral medicine for the treatment of COVID-19, in Whitby, Ont. The companies will manufacture Molnupiravir for distribution in Canada and the U.K., as well as markets in Europe, Asia and Latin America, pending local market approvals.

Source name:

Unique identifier: CP143756471

Legacy Identifier: r_COVID-Treatment20211206T1330

Type: Video

Duration: 2m38s

Dimensions: 1920px × 1080px 195.98 MB

Usage rights: FOR ONE TIME USE ONLY. NO STORAGE FOR FUTURE USE.

Create Date: 12/6/2021 1:30:00 PM

Display aspect ratio: 16:9